- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01875419
Non-invasive Brain Stimulation and Cognitive Processing in Depression
Neural, Cognitive, and Clinical Effects of Prefrontal Cortex Stimulation to Enhance Psychotherapy in Depression: a Double-blind Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We propose to investigate the effect of applying transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (LDLPFC) immediately prior to each of 8 sessions of cognitive behavioural therapy (CBT), a type of psychological therapy. In addition we will investigate whether tDCS effects on CBT are due to changes in cognitive control using both behavioural and neuroimaging measures.
We hypothesize that tDCS, thanks to its enduring effects, should improve the benefits of CBT, through the enhancement of cognitive control in the patient.
Null hypothesis: mood and cognitive performance will be equivalent in depressed individuals who undergo tDCS and those who undergo sham stimulation.
Experimental hypothesis: mood and cognitive performance will be improved in depressed individuals who undergo tDCS relative to those who undergo sham stimulation.
Sixty patients suffering from depression will be recruited, and a double-blind, sham-controlled, randomised design will be used. This design means that neither participants nor researchers are aware of the conditions they have been assigned to, and has been chosen to eliminate participant expectancy ("placebo") effects and researcher bias. To ensure that 30 participants are included in each group, we will use a balanced assignment algorithm at entry into the study, which will maximise statistical power. Since the results of a study of this type have never previously been reported (to our knowledge), clinical equipoise exists, mandating the use of a sham stimulation arm. Patients with depression will be randomly assigned to one of two groups: tDCS or sham stimulation. To ensure that 30 participants are included in each group, we will use a balanced assignment algorithm at entry into the study. The whole study will be spread over 16 weeks for each participant with the following time course:
- start: baseline MRI brain scan while completing a cognitive control task; measures of depressive symptoms
- weeks 1 to 8: one session per week of tDCS or sham stimulation (20 min, while completing a cognitive control task) immediately followed by CBT (1 hour); measures of depressive symptoms
- end of week 8: post-treatment MRI scan while completing a cognitive control task and measures of depressive symptoms
- week 9 to 16: up to one session per week of CBT as usual (1 hour) without stimulation
- end of week 16, or end of CBT (whichever is sooner): measures of depressive symptoms
MRI scans will have two purposes, (1) localising the area of the DLPFC for stimulation, and (2) comparing brain responses to a cognitive control task before and after treatment.
The tDCS will be delivered using neuroConn stimulators. A 1 milliamp (mA) current will be delivered for 20 minutes through damp sponges soaked in saline solution and attached to the head of the patient using a cap. One electrode will be placed on the forehead over the LDLPFC, and the other on the left shoulder blade or left cheek to record baseline electrical signal. In the sham condition, there will be a brief current change at the beginning and end of each stimulation session, in order to mimic the effect of an actual stimulation, but no current will be delivered in between.
CBT sessions will be delivered weekly, immediately after the tDCS or sham stimulation for the first 8 weeks, and provided by qualified psychological therapists as part of standard National Health Services (NHS) care.
Mood will be assessed before the start of the study (first MRI scan), each week for the 8 week stimulation phase, at the second MRI scan and after 16 weeks, using the Montgomery and Asberg Depression Rating Scale (MADRS).
Patients will perform a task to assess their cognitive control abilities during the MRI scans, as well as during each of the 8 stimulation sessions. During this task, visual stimuli will be presented to the subject, who will have to make different responses to these stimuli by pressing buttons on a response box.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, WC1N 3AR
- UCL Institute of Cognitive Neuroscience
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients suffering from unipolar major depressive disorder
- First depressive episode onset before 40 years old
- Right-handedness
- English as first language
- Intention to commence a course of cognitive behavioural therapy
Exclusion Criteria:
- Antidepressant or other psychotropic medication at any time during the study or within previous 4 weeks (8 for fluoxetine)
- Recent illicit drug use
- Prior mixed, manic, or psychotic symptoms or other psychiatric or neurological illness
- Standard exclusion criteria for MRI scanning: pregnancy, breast feeding, any immovable metal in the body, weight above 250 lbs, claustrophobia
- tDCS safety criteria: skin disease or skin treatment that could potentially cause irritation with electrical stimulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients tDCS
A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
|
Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT. Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between.
Other Names:
8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
|
Sham Comparator: Patients - Sham
Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
|
8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beck Depression Inventory (BDI) score
Time Frame: Change from Baseline BDI score at 8 sessions
|
BDI scores will constitute a self-report measure of depression symptoms over the course of the trial.
|
Change from Baseline BDI score at 8 sessions
|
Beck Depression Inventory (BDI) score
Time Frame: Change from Baseline BDI score at 16 sessions or when the patient ceases CBT, whichever came first
|
BDI scores will constitute a self-report measure of depression.
|
Change from Baseline BDI score at 16 sessions or when the patient ceases CBT, whichever came first
|
Hamilton Depression Rating Scale (HAMD)
Time Frame: Change from Baseline HAMD at 8 CBT sessions
|
HAMD scores will constitute an interview scale from baseline to end of tDCS.
|
Change from Baseline HAMD at 8 CBT sessions
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive Control Performance
Time Frame: Week 0 (Baseline), 1, 2, 3, 4, 5, 6, 7, 8, and 9
|
Evolution of behavioral performance on the cognitive control task over the course of the trial, performed inside the scanner at baseline and after session 8, and during tDCS stimulation once a week for 8 weeks.
|
Week 0 (Baseline), 1, 2, 3, 4, 5, 6, 7, 8, and 9
|
Functional Magnetic Resonance Imaging (fMRI) data
Time Frame: Change from Baseline brain responses to the cognitive control task at week 9
|
Brain responses to the cognitive control task in the LDLPFC and other relevant brain region will be analysed and compared after relative to before treatment.
|
Change from Baseline brain responses to the cognitive control task at week 9
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Stephen Pilling, PhD, University College, London
- Principal Investigator: Jonathan P Roiser, PhD, University College, London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13/0256
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unipolar Major Depressive Disorder
-
Posit Science CorporationNational Institute of Mental Health (NIMH); University of MinnesotaCompletedMajor Depressive DisorderUnited States
-
Mayo ClinicEnrolling by invitationMajor Depressive Disorder | Unipolar, Non-psychotic Major Depressive DisorderUnited States
-
National Institute of General Medical Sciences...CompletedMajor Depression | Major Depressive Disorder | Unipolar DepressionUnited States
-
Centre Psychothérapique de NancyLUCIMEDCompletedMajor Depressive Disorder | Unipolar DepressionFrance
-
Ludwig-Maximilians - University of MunichCompletedDepression | Major Depressive Disorder | Unipolar DepressionGermany
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedMajor Depressive Disorder | Unipolar DepressionBrazil
-
Yuqi ChengUnknownMajor Depressive Disorder | Depression, UnipolarChina
-
University of Sao PauloUnknown
-
University of PennsylvaniaActive, not recruitingDepressive Disorder | Depression | Major Depressive Disorder | Depression, UnipolarUnited States
-
Kirk Erickson, PhDCompletedDepressive Disorder | Depression | Depressive Disorder, Major | Major Depressive Disorder | Unipolar DepressionUnited States
Clinical Trials on Transcranial direct current stimulation (tDCS)
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States
-
Charite University, Berlin, GermanyTerminatedNeuralgia | Neuropathic PainGermany
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
Massachusetts General HospitalRecruitingAttention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
Oslo University HospitalCompleted
-
The National Brain Mapping Laboratory (NBML)Neuroelectrics Corporation; Leibniz-Institut für Arbeitsforschung; Zanjan University...CompletedDepressive Disorder | Cognitive Impairment | Psychiatric DisorderIran, Islamic Republic of
-
Hospital de Clinicas de Porto AlegreUnknownChronic Pain | EndometriosisBrazil
-
Pusan National University Yangsan HospitalRecruiting
-
VA Office of Research and DevelopmentRecruitingSuicide | ImpulsivityUnited States
-
VA Office of Research and DevelopmentRecruitingObesityUnited States